Another company looking to initiate clinical trials with an epigenetic-editor-based treatment for hepatitis is nChroma Bio.

The pharmaceutical company says it will continue to operate its production facility near Research Triangle Park.

Enterprises are transforming into AI-native entities by embedding AI into their core operations, moving beyond predictive ...

Tune Therapeutics and Biogen. As of Wednesday, Novartis was the 55th largest public company in the world with a market value above $200 billion. Enjoy Triangle tech news? Subscribe to Open Source ...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.

North Carolina-based biotech Tune Therapeutics has raised $175 million in a Series B that will help it to take its lead epigenetic silencing drug, Tune-401, into clinical testing as a potential ...

He is the head of HHS, and yet he continues to spout untested, unproven therapies and has only given a very lukewarm ...

Introducing TxGemma: Open models to improve therapeutics development - Google ... and can also fine-tune it to adapt it to their own treatment data and tasks. A Colab notebook is also available ...

ADC Therapeutics' primary focus is on the CD19 ... And considering DLBCL itself is a market sized to the tune of $4 billion annually, there is still a lot of opportunity. Also, not discussed ...

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...